Skip to main content

Advertisement

SpringerLink
Log in

New Antifungal Agents and New Formulations Against Dermatophytes

  • Published:
Mycopathologia Aims and scope Submit manuscript

Abstract

A variety of oral and topical antifungal agents are available for the treatment of superficial fungal infections caused by dermatophytes. This review builds on the antifungal therapy update published in this journal for the first special issue on Dermatophytosis (Gupta and Cooper 2008;166:353–67). Since 2008, there have not been additions to the oral antifungal armamentarium, with terbinafine, itraconazole, and fluconazole still in widespread use, albeit for generally more severe or recalcitrant infections. Griseofulvin is used in the treatment of tinea capitis. Oral ketoconazole has fallen out of favor in many jurisdictions due to risks of hepatotoxicity. Topical antifungals, applied once or twice daily, are the primary treatment for tinea pedis, tinea corporis/tinea cruris, and mild cases of tinea unguium. Newer topical antifungal agents introduced include the azoles, efinaconazole, luliconazole, and sertaconazole, and the oxaborole, tavaborole. Research is focused on developing formulations of existing topical antifungals that utilize novel delivery systems in order to enhance treatment efficacy and compliance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nweze EI, Eke I. Dermatophytosis in northern Africa. Mycoses. 2016;59:137–44.

    Article  CAS  PubMed  Google Scholar 

  2. Panthagani AP, Tidman MJ. Diagnosis directs treatment in fungal infections of the skin. The Practitioner. 2015;259(25–9):3.

    Google Scholar 

  3. Rosen T. Mycological considerations in the topical treatment of superficial fungal infections. J Drugs Dermatol. 2016;15:49–55.

    Google Scholar 

  4. Murmu S, Debnath C, Pramanik AK, et al. Detection and characterization of zoonotic dermatophytes from dogs and cats in and around Kolkata. Vet World. 2015;8:1078–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: a comprehensive review. Indian Dermatol Online J. 2016;7:77–86.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jaradat SW, Cubillos S, Krieg N, et al. Low DEFB4 copy number and high systemic hBD-2 and IL-22 levels are associated with dermatophytosis. J Invest Dermatol. 2015;135:750–8.

    Article  CAS  PubMed  Google Scholar 

  7. Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for investigative dermatology. J Am Acad Dermatol. 2006;55:490–500.

    Article  PubMed  Google Scholar 

  8. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641–8.

    Article  CAS  PubMed  Google Scholar 

  9. Panackal A, Halpern E, Watson A. Cutaneous fungal infections in the United States: analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995–2004. Int J Dermatol. 2009;48:704–12.

    Article  PubMed  Google Scholar 

  10. Sais G, Jucglà A, Peyrí J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol. 1995;132:758–61.

    Article  CAS  PubMed  Google Scholar 

  11. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol. 1992;126(Suppl 39):23–7.

    Article  PubMed  Google Scholar 

  12. Heikkilä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol. 1995;133:699–703.

    Article  PubMed  Google Scholar 

  13. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl 4):2–15.

    Article  PubMed  Google Scholar 

  14. Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems [Internet]. 2013. http://www.fda.gov/drugs/drugsafety/ucm362415.htm.

  15. Al Hasan M, Fitzgerald SM, Saoudian M, Krishnaswamy G. Dermatology for the practicing allergist: tinea pedis and its complications. Clin Mol Allergy. 2004;2:5.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ilkit M, Durdu M. Tinea pedis: the etiology and global epidemiology of a common fungal infection. Crit Rev Microbiol. 2014;41:374–88.

    Article  PubMed  Google Scholar 

  17. Stein GLF, Vlahovic T, Verma A, Olayinka B, Fleischer AB. Naftifine hydrochloride gel 2%: an effective topical treatment for moccasin-type Tinea pedis. J Drugs Dermatol. 2015;14:1138–44.

    Google Scholar 

  18. Caputo R, De Boulle K, Del Rosso J, Nowicki R. Prevalence of superficial fungal infections among sports-active individuals: results from the Achilles survey, a review of the literature. J Eur Acad Dermatol Venereol. 2001;15:312–6.

    CAS  PubMed  Google Scholar 

  19. Semel JD, Goldin H. Association of athlete’s foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis. 1996;23:1162–4.

    Article  CAS  PubMed  Google Scholar 

  20. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166:353–67.

    Article  PubMed  Google Scholar 

  21. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil)—a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol. 1989;14:124–7.

    Article  CAS  PubMed  Google Scholar 

  22. Novartis Pharmaceuticals Canada Inc. Pr LAMISIL* (terbinafine hydrochloride) 250 mg tablets (expressed as base) topical cream 1% w/w (10 mg/g) topical spray solution 1% w/w (10 mg/g) Antifungal Agent [Internet]. 2016. http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=14532&lang=eng. Accessed 14 April 2016.

  23. Tausch I, Decroix J, Gwiezdzinski Z, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatol. 1998;37:140–2.

    Article  CAS  PubMed  Google Scholar 

  24. Diflucan (Fluconazole Tablets) (Fluconazole for Oral Suspension) [Internet]. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019949s060,020090s044lbl.pdf. Accessed 22 April 2016.

  25. Nozickova M, Koudelkova V, Kulikova Z, et al. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol. 1998;37:703–5.

    Article  CAS  PubMed  Google Scholar 

  26. Terbinafine [Internet]. PubChem2016 [cited 2016 Apr 26]: https://pubchem.ncbi.nlm.nih.gov/compound/1549008.

  27. Itraconazole [Internet]. PubChem2016 [cited 2016 Apr 26]: https://pubchem.ncbi.nlm.nih.gov/compound/55283.

  28. Fluconazole [Internet]. PubChem2016 [cited 2016 Apr 26]: https://pubchem.ncbi.nlm.nih.gov/compound/3365.

  29. Hu Z, Zhang J, Cheng X. Antifungal efficiency of miconazole and econazole and the interaction with transport protein: a comparative study. Pharm Biol. 2015;53:251–61.

    Article  CAS  PubMed  Google Scholar 

  30. Lamisil AT. Terbinafine hydrochloride cream 1% antifungal. Full prescription strength cream. [Internet]. FDA US Food Drug Adm. 2007 [cited 2016 Apr 26]: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020980s005lbl.pdf.

  31. Loprox cream (cicloporix) 0.77% [Internet]. [cited 2016 Apr 26]: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018748s024,019824s023,020519s016lbl.pdf.

  32. Seebacher C, Nietsch KH, Ulbricht HM. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. Cutis. 2001;68:17–22.

    CAS  PubMed  Google Scholar 

  33. Weir S, Patton L, Castle K, et al. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy. J Clin Pharm Ther. 2011;36:128–37.

    Article  CAS  PubMed  Google Scholar 

  34. Apo-ciclopirox, ciclopirox (topical solution 8% w/w). Product monograph. Health Can Prod Drug Data Base Apotex Inc Aug 28, Inc. 2007. http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=78435&lang=eng. Accessed 22 April 2016.

  35. Gupta AK, Skinner AR, Cooper EA. Evaluation of the efficacy of ciclopirox 0.77% gel in the treatment of tinea pedis interdigitalis (dermatophytosis complex) in a randomized, double-blind, placebo-controlled trial. Int J Dermatol. 2005;44:590–3.

    Article  CAS  PubMed  Google Scholar 

  36. Valeant INTL. ERTACZO (SERTACONAZOLE NITRATE) CREAM, 2% [Internet]. 2003 [cited 2016 Mar 10]: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21385_Ertaczo_lbl.pdf. Accessed 22 April 2016.

  37. Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69:339–59.

    Article  CAS  PubMed  Google Scholar 

  38. Borelli C, Klövekorn G, Ernst T-M, et al. Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigitalis, or a corresponding candidosis. Am J Clin Dermatol. 2007;8:371–8.

    Article  PubMed  Google Scholar 

  39. Scher RK, Nakamura N, Tavakkol A. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses. 2014;57:389–93.

    Article  CAS  PubMed  Google Scholar 

  40. Jarratt M, Jones T, Adelglass J, et al. Efficacy and safety of once-daily luliconazole 1% cream in patients ≥12 years of age with interdigital tinea pedis: a phase 3, randomized, double-blind, vehicle-controlled study. J Drugs Dermatol. 2014;13:838–46.

    CAS  PubMed  Google Scholar 

  41. Elewski BE, Vlahovic TC. Econazole nitrate foam 1% for the treatment of tinea pedis: results from two double-blind, vehicle-controlled, phase 3 clinical trials. J Drugs Dermatol. 2014;13:803–8.

    CAS  PubMed  Google Scholar 

  42. Monk JP, Brogden RN. Naftifine. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs. 1991;42:659–72.

    Article  CAS  PubMed  Google Scholar 

  43. Evans EG, James IG, Seaman RA, Richardson MD. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol. 1993;129:437–42.

    Article  CAS  PubMed  Google Scholar 

  44. Rotta I, Ziegelmann PK, Otuki MF, et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013;149:341–9.

    Article  CAS  PubMed  Google Scholar 

  45. Bell-Syer SEM, Khan SM, Torgerson DJ. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev. 2012;10:CD003584.

    PubMed  Google Scholar 

  46. Merlin K, Kilkenny M, Plunkett A, Marks R. The prevalence of common skin conditions in Australian school students: 4 Tinea pedis. Br J Dermatol. 1999;140:897–901.

    Article  CAS  PubMed  Google Scholar 

  47. Hammer TR, Mucha H, Hoefer D. Dermatophyte susceptibility varies towards antimicrobial textiles. Mycoses. 2012;55:344–51.

    Article  PubMed  Google Scholar 

  48. Fujiwara Y, Kishida K, Terao M, et al. Beneficial effects of foot care nursing for people with diabetes mellitus: an uncontrolled before and after intervention study. J Adv Nurs. 2011;67:1952–62.

    Article  PubMed  Google Scholar 

  49. Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. Dermatol Clin. 2003;21:395–400.

    Article  PubMed  Google Scholar 

  50. Moriarty B, Hay R, Morris-Jones R. The diagnosis and management of tinea. BMJ. 2012;345:e4380.

    Article  PubMed  Google Scholar 

  51. van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. Br J Dermatol. 2015;172:616–41.

    Article  PubMed  Google Scholar 

  52. Alston SJ, Cohen BA, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal/corticosteroid agents. Pediatrics. 2003;111:201–3.

    Article  PubMed  Google Scholar 

  53. Gupta AK, Cooper EA, Ryder JE, et al. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol. 2004;5:225–37.

    Article  PubMed  Google Scholar 

  54. Verma SB, Vasani R. Male genital dermatophytosis–clinical features and the effects of the misuse of topical steroids and steroid combinations—an alarming problem in India. Mycoses. 2016. doi:10.1111/myc.12503.

    Google Scholar 

  55. Choudhary S, Bisati S, Singh A, Koley S. Efficacy and safety of terbinafine hydrochloride 1% cream versus sertaconazole nitrate 2% cream in Tinea corporis and Tinea cruris: a comparative therapeutic trial. Indian J Dermatol. 2013;58:457–60.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Shivamurthy RPM, Reddy SGH, Kallappa R, et al. Comparison of topical anti- fungal agents sertaconazole and clotrimazole in the treatment of tinea corporis-an observational study. J Clin Diagn Res. 2014;8:HC09–12.

    PubMed  PubMed Central  Google Scholar 

  57. Pande VV, Kadnor NA, Kadam RN, Upadhye SA. Fabrication and characterization of sertaconazole nitrate microsponge as a topical drug delivery system. Indian J Pharm Sci. 2015;77:675–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Sahoo S, Pani NR, Sahoo SK. Effect of microemulsion in topical sertaconazole hydrogel: in vitro and in vivo study. Drug Deliv. 2016;23:338–45.

    Article  CAS  PubMed  Google Scholar 

  59. Gupta AK, Daigle D. A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections. Infect Drug Resist. 2016;9:1–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Jones TM, Jarratt MT, Mendez-Moguel I, et al. A randomized, multicenter, double-blind, vehicle-controlled study evaluating the efficacy and safety of luliconazole cream 1% once daily for 7 days in patients aged ≥12 years with tinea cruris. J Drugs Dermatol. 2014;13:32–8.

    CAS  PubMed  Google Scholar 

  61. Jerajani H, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: a pilot study. Indian J Dermatol. 2013;58:34–8.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Selvan AT, Girisha G, Suthakaran R. Comparative evaluation of newer topical antifungal agents in the treatment of superficial fungal infections (tinea or dermatophytic). Int Res J Pharm. 2013;4:224–8.

    Article  Google Scholar 

  63. Choudhary SV, Aghi T, Bisati S. Efficacy and safety of terbinafine hydrochloride 1% cream versus eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris. Indian Dermatol Online J. 2014;5:128–31.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Khosravi AR, Shokri H, Vahedi G. Factors in etiology and predisposition of adult Tinea capitis and review of published literature. Mycopathologia. 2016;181:371–8.

    Article  PubMed  Google Scholar 

  65. Fuller LC, Barton RC, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the management of tinea capitis 2014. Br J Dermatol. 2014;171:454–63.

    Article  CAS  PubMed  Google Scholar 

  66. Bortolussi R, Martin S, Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Antifungal agents for common outpatient paediatric infections. 2014. http://www.cps.ca/documents/position/antifungal-agents-common-infections. Accessed 22 April 2016.

  67. Gonzalez U, Seaton T, Bergus G, Jacobson J, Martinez-Monzon C. Systemic antifungal therapy for tinea capitis in children (Review). Cochrane Database Syst Rev. 2007;CD004685.

  68. Mashiah J, Kutz A, Ben Ami R, et al. Tinea capitis outbreak among paediatric refugee population, an evolving healthcare challenge. Mycoses. 2016. doi:10.1111/myc.12501.

    PubMed  Google Scholar 

  69. Bortolussi R, Martin S. Antifungal agents for common outpatient paediatric infections. Can Paediatr Soc. 2016;1–5. http://www.cps.ca/documents/position/antifungal-agents-common-infections. Accessed 22 April 2016.

  70. Suh D-C, Friedlander SF, Raut M, et al. Tinea capitis in the United States: diagnosis, treatment, and costs. J Am Acad Dermatol. 2006;55:1111–2.

    Article  PubMed  Google Scholar 

  71. del Boz J, Crespo V, Rivas-Ruiz F, de Troya M. A 30 year survey of paediatric tinea capitis in southern Spain. J Eur Acad Dermatol Venereol. 2011;25:170–4.

    Article  PubMed  Google Scholar 

  72. Elewski BE. Tinea capitis: a current perspective. J Am Acad Dermatol. 2000;42:1–20.

    Article  CAS  PubMed  Google Scholar 

  73. Brilhante RSN, Cordeiro RA, Rocha MFG, et al. Tinea capitis in a dermatology center in the city of Fortaleza, Brazil: the role of Trichophyton tonsurans. Int J Dermatol. 2004;43:575–9.

    Article  PubMed  Google Scholar 

  74. Mebazaa A, Oumari KEL, Ghariani N, et al. Tinea capitis in adults in Tunisia. Int J Dermatol. 2010;49:513–6.

    Article  PubMed  Google Scholar 

  75. Zur RL, Shapero J, Shapero H. Barriers to treatment of Tinea capitis in children living in the Jane Finch community of Toronto. J Cutan Med Surg. 2015;19:484–7.

    Article  PubMed  Google Scholar 

  76. Chen C, Koch LH, Dice JE, et al. A randomized, double-blind study comparing the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. Pediatr Dermatol. 2010;27:459–62.

    Article  PubMed  Google Scholar 

  77. González U, Seaton T, Bergus G, Jacobson J, Martínez-Monzón C. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2007;CD004685.

  78. Lamisil. Package Insert: LAMISIL (terbinafine hydrochloride) Tablets, 250 mg Drugs@FDA: FDA Approved Drug Products 2012 [Internet]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf. Accessed 22 April 2016.

  79. Annex 1 19th WHO Model List of Essential Medicines [Internet]. 2015 [cited 2016 Apr 25]: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf.

  80. Grifulvin V. Griseofulvin Tablets, USP (Microsize) and Griseofulvin Oral Suspension, USP (Microsize) [Internet]. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/062279s022lbl.pdf. Accessed 22 April 2016.

  81. Abdel-Rahman SM, Herron J, Fallon-Friedlander S, et al. Pharmacokinetics of terbinafine in young children treated for tinea capitis. Pediatr Infect Dis J. 2005;24:886–91.

    Article  PubMed  Google Scholar 

  82. Seebacher C, Abeck D, Brasch J, et al. Tinea capitis. J Dtsch Dermatol Ges. 2006;4:1085–91.

    Article  PubMed  Google Scholar 

  83. Gupta AK, Alexis ME, Raboobee N, et al. Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. Br J Dermatol. 1997;137:251–4.

    Article  CAS  PubMed  Google Scholar 

  84. Pfizer. Diflucan tablets (Fluconazole) Label Information [Internet]. 2011 [cited 2012 May 30] http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s055,019950s059,020090s038lbl.pdf.

  85. Shemer A, Plotnik IB, Davidovici B, et al. Treatment of tinea capitis–griseofulvin versus fluconazole—a comparative study. J Dtsch Dermatol Ges. 2013;11(737–41):737–42.

    PubMed  Google Scholar 

  86. Allen HB, Honig PJ, Leyden JJ, McGinley KJ. Selenium sulfide: adjunctive therapy for tinea capitis. Pediatrics. 1982;69:81–3.

    CAS  PubMed  Google Scholar 

  87. Greer DL. Treatment of tinea capitis with itraconazole. J Am Acad Dermatol. 1996;35:637–8.

    Article  CAS  PubMed  Google Scholar 

  88. White JML, Higgins EM, Fuller LC. Screening for asymptomatic carriage of Trichophyton tonsurans in household contacts of patients with tinea capitis: results of 209 patients from South London. J Eur Acad Dermatol Venereol. 2007;21:1061–4.

    Article  CAS  PubMed  Google Scholar 

  89. Shemer A, Grunwald MH, Gupta AK, et al. Griseofulvin and fluconazole reduce transmission of Tinea capitis in schoolchildren. Pediatr Dermatol. 2015;32:696–700.

    Article  PubMed  Google Scholar 

  90. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641–8.

    Article  CAS  PubMed  Google Scholar 

  91. Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014;15:489–502.

    Article  PubMed  Google Scholar 

  92. Gupta AK, Ryder JE. The use of oral antifungal agents to treat onychomycosis. Dermatol Clin. 2003;21:469–79.

    Article  CAS  PubMed  Google Scholar 

  93. de Sá DC, Lamas APB, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014;15:17–36.

    PubMed  Google Scholar 

  94. Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014;6:601–12.

    PubMed  PubMed Central  Google Scholar 

  95. Zaug M. Amorolfine nail lacquer: clinical experience in onychomycosis. J Eur Acad Dermatol Venereol. 1995;4:S23–30.

    Article  Google Scholar 

  96. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43:S70–80.

    Article  CAS  PubMed  Google Scholar 

  97. Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600–8.

    Article  CAS  PubMed  Google Scholar 

  98. Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62–9.

    Article  CAS  PubMed  Google Scholar 

  99. Hammer TR, Mucha H, Hoefer D. Infection risk by dermatophytes during storage and after domestic laundry and their temperature-dependent inactivation. Mycopathologia. 2011;171:43–9.

    Article  PubMed  Google Scholar 

  100. Gupta AK, Elewski BE, Rosen T, et al. Onychomycosis: strategies to minimize recurrence. J Drugs Dermatol. 2016;15:279–82.

    CAS  PubMed  Google Scholar 

  101. Sigurgeirsson B, Olafsson J, Steinsson J, Kerrouche N, Sidou F. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol. 2010;24:910–5.

    Article  CAS  PubMed  Google Scholar 

  102. Gupta AK, Daigle D, Foley KA. Network meta-analysis of onychomycosis treatments. Skin Appendage Disord. 2015;1:74–81.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol. 2013;27:267–72.

    Article  CAS  PubMed  Google Scholar 

  104. Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66:494–502.

    Article  PubMed  Google Scholar 

  105. Sigurgeirsson B, Billstein S, Rantanen T, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil versus itraconazole in onychomycosis. Br J Dermatol. 1999;141(Suppl 56):5–14.

    Article  PubMed  Google Scholar 

  106. Iorizzo M, Hartmane I, Derveniece A, Mikazans I. Ciclopirox 8% HPCH nail lacquer in the treatment of mild-to-moderate onychomycosis: a randomized, double-blind amorolfine controlled study using a blinded evaluator. Skin Appendage Disord. 2016;1:134–40.

    Article  PubMed  Google Scholar 

  107. Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol. 2009;23:773–81.

    Article  CAS  PubMed  Google Scholar 

  108. Gupta A, Cernea M. How effective is efinaconazole in the management of onychomycosis? Expert Opin Pharmacother. 2016;17:611–8.

    Article  PubMed  Google Scholar 

  109. Gupta AK, Daigle D. Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults. Expert Rev Anti Infect Ther. 2014;12:735–42.

    Article  CAS  PubMed  Google Scholar 

  110. Gupta AK, Studholme C. Novel investigational therapies for onychomycosis: an update. Expert Opin Investig Drugs. 2016;25:297–305.

    Article  CAS  PubMed  Google Scholar 

  111. Sakamoto M, Sugimoto N, Kawabata H, et al. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails. J Drugs Dermatol. 2014;13:1388–92.

    CAS  PubMed  Google Scholar 

  112. Alley MR, Baker SJ, Beutner KR, Plattner J. Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs. 2007;16:157–67.

    Article  CAS  PubMed  Google Scholar 

  113. Olafsson JH. Combination therapy for onychomycosis. Br J Dermatol. 2003;149:15–8.

    Article  CAS  PubMed  Google Scholar 

  114. Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatol Treat. 2005;16:327–30.

    Article  CAS  Google Scholar 

  115. Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol. 2007;157:149–57.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Toronto, Toronto, Canada

    Aditya K. Gupta

  2. Mediprobe Research Inc., 645 Windermere Road, London, ON, Canada

    Aditya K. Gupta, Kelly A. Foley & Sarah G. Versteeg

Authors
  1. Aditya K. Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelly A. Foley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah G. Versteeg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aditya K. Gupta.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, A.K., Foley, K.A. & Versteeg, S.G. New Antifungal Agents and New Formulations Against Dermatophytes. Mycopathologia 182, 127–141 (2017). https://doi.org/10.1007/s11046-016-0045-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11046-016-0045-0

Keywords

Search

Navigation